Eli Lilly CEO Says Cost Cutting Won’t Solve Drug Sales Loss

Eli Lilly & Co., facing generic competition to two of its top drugs, needs to rely on new medicines rather than cost-cutting to overcome the revenue loss, Chief Executive Officer John Lechleiter said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.